Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD117 CAR-iNKT-IL15 cells
- Development stage
- Preclinical
- Lead developer
- Stanford University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD117 CAR-iNKT-IL15 cells are an experimental, off-the-shelf allogeneic cell therapy designed for the treatment of acute myeloid leukemia (AML). This therapy utilizes invariant natural killer T (iNKT) cells, a unique population of innate-like T cells that recognize glycolipids presented by CD1d and are known for their ability to mediate antitumor activity without inducing graft-versus-host disease (GVHD). The cells are engineered with a chimeric antigen receptor (CAR) targeting CD117 (c-Kit), a receptor tyrosine kinase highly expressed on AML blasts. To overcome functional exhaustion and enhance persistence, the CAR construct incorporates interleukin-15 (IL-15). Preclinical research conducted at Stanford University indicates that these cells can effectively eliminate CD117-high AML cells and CD1d-positive tumor-associated macrophages, potentially reversing the immunosuppressive tumor microenvironment associated with aggressive leukemia.
- Other names
- CD117-targeted CAR-iNKT cellsCD-117-targeted CAR-iNKT cellsCD 117-targeted CAR-iNKT cellsallogeneic CD117 CAR-iNKT-IL15 cells
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)iNKT TCR (Invariant natural killer T-cell receptor)
Beyond the preview
Go deeper on CD117 CAR-iNKT-IL15 cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD117 CAR-iNKT-IL15 cells.